The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2MrhCSr